Use of akkermansia for treating metabolic disorders

Abstract

The present invention relates to Akkermansia muciniphila or fragments thereof for treating a metabolic disorder in a subject in need thereof. The present invention also relates to a composition, a pharmaceutical composition and a medicament comprising Akkermansia muciniphila or fragments thereof for treating a metabolic disorder. The present invention also relates to the use of Akkermansia muciniphila or fragments thereof for promoting weight loss in a subject in need thereof.

1 . A method for treating a metabolic disorder or for increasing satiety in a subject in need thereof, the method comprising administering  Akkermansia muciniphila  or fragments thereof to the subject. 
     
     
         2 . The method of  claim 1 , wherein said metabolic disorder is obesity. 
     
     
         3 . The method of  claim 1 , wherein said metabolic disorder is selected from the group comprising metabolic syndrome, insulin-deficiency or insulin-resistance related disorders, Diabetes Mellitus (such as, for example, Type 2 Diabetes), glucose intolerance, abnormal lipid metabolism, atherosclerosis, hypertension, cardiac pathology, stroke, non-alcoholic fatty liver disease, hyperglycemia, hepatic steatosis, dyslipidemia, dysfunction of the immune system associated with overweight and obesity, cardiovascular diseases, high cholesterol, elevated triglycerides, asthma, sleep apnoea, osteoarthritis, neuro-degeneration, gallbladder disease, syndrome X, inflammatory and immune disorders, atherogenic dyslipidemia and cancer. 
     
     
         4 . A method for increasing energy expenditure of a subject, optionally without impacting the food intake of said subject, the method comprising administering  Akkermansia muciniphila  or fragments thereof to the subject. 
     
     
         5 . (canceled) 
     
     
         6 . The method of  claim 1 , wherein viable cells of  Akkermansia muciniphila  are administered to the subject in need thereof. 
     
     
         7 . The method of  claim 1 , wherein  Akkermansia muciniphila  is orally administered. 
     
     
         8 . The method of  claim 1 , wherein an amount of  Akkermansia muciniphila  is ranging from about 1.10 4  to about 1.10 12  cfu, from about 1.10 5  to about 1.10 11  cfu, or from about 1.10 6  to about 1.10 10  cfu is administered to the subject. 
     
     
         9 . The method of  claim 1 , wherein the  Akkermansia muciniphila  is administered at least three times a week. 
     
     
         10 . The method of  claim 1 , wherein the  Akkermansia muciniphila  is co-administered with another probiotic strain and/or with one or more prebiotics. 
     
     
         11 . The method of  claim 1 , wherein the  Akkermansia muciniphila  is administered as a composition in association with an excipient. 
     
     
         12 . The method of  claim 11 , wherein said composition is a nutritional composition. 
     
     
         13 . The method of  claim 11 , wherein said composition is orally administered. 
     
     
         14 . The method of  claim 1 , wherein the  Akkermansia muciniphila  is administered as a pharmaceutical composition in association with a pharmaceutically acceptable vehicle. 
     
     
         15 . (canceled) 
     
     
         16 . A method for promoting weight loss in a subject in need thereof, the method comprising administering  Akkermansia muciniphila  or fragments thereof to the subject. 
     
     
         17 . (canceled)